ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice
Status: Completed
Location: See all (39) locations...
Study Type: Observational
SUMMARY
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• \- Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral implant in at least one eye.
Locations
United States
California
Angeles Eye Institute /ID# 240368
Culver City
Hamilton Glaucoma Center Shiley Eye Center UCSD /ID# 240364
La Jolla
American Institute of Research /ID# 247820
Los Angeles
North Bay Eye Associates Inc. /ID# 240362
Petaluma
Pacific Eye Associates /ID# 240536
San Francisco
Colorado
Colorado Eye Institute /ID# 240798
Colorado Springs
ICON Eye Care /ID# 240681
Grand Junction
Florida
Eye Associates of Fort Meyers /ID# 244476
Fort Myers
MedEye Associates /ID# 240374
Miami
Center for Sight - Sarasota /ID# 244578
Sarasota
Newsom Eye & Laser Center /ID# 253287
Sebring
Dr. Andrew Gardner Logan, FL /ID# 240361
Tamarac
Your Eye Specialists /ID# 253286
Weston
Georgia
Georgia Eye Partners /ID# 240061
Atlanta
Illinois
Kovach Eye Institute /ID# 244581
Elmhurst
Kansas
Stiles Eyecare Excellence /ID# 240376
Overland Park
Kentucky
The Eye Care Institute /ID# 240367
Louisville
Maryland
John Hopkins Wilmer Eye Institute /ID# 243701
Bethesda
Missouri
Midwest Vision Research Foundation at Pepose Vision Institute /ID# 240537
Chesterfield
Wiles Eye Center /ID# 240808
Kansas City
Ophthalmology Associates /ID# 240799
St Louis
North Carolina
Duke Eye Center /ID# 244478
Durham
North Dakota
Bergstrom Eye Research LLC /ID# 240363
Fargo
New Jersey
Eye Associates of North Jersey /ID# 244585
Dover
Hudson Eye /ID# 240805
Jersey City
Glaucoma Care Center /ID# 252021
Livingston
Burlington County Eye Physicians /ID# 244594
Willingboro
New York
MaculaCare PLLC /ID# 244593
New York
New York New Jersey Eye Institute /ID# 244590
Orangeburg
New York Eye Surgery Associates, PLLC /ID# 244592
The Bronx
Ohio
META Medical Research Institute, LLC /ID# 240800
Dayton
Oklahoma
Oklahoma Eye Surgeons /ID# 240373
Oklahoma City
Pennsylvania
Scott and Christie and Associates /ID# 244574
Cranberry Township
Tennessee
Vanderbilt University Medical Center /ID# 244577
Nashville
Texas
Glaucoma Associates of Texas /ID# 240682
Dallas
Glaucoma Associates of Texas /ID# 253289
Dallas
El Paso Eye Surgeons, P.A. /ID# 240366
El Paso
DCT Shah Eye Research Institut /ID# 240375
Mission
Wisconsin
The Eye Centers of Racine and Kenosha LTD /ID# 240059
Racine
Time Frame
Start Date: 2021-03-03
Completion Date: 2024-07-12
Participants
Target number of participants: 220
Treatments
Bimatoprost intracameral implant (DURYSTA) 10μg
Patients with OAG or OHT who are scheduled for intracameral administration of a bimatoprost intracameral implant by their ophthalmologist.
Related Therapeutic Areas
Sponsors
Leads: Allergan